MedTrace Logo

Escitalopram in Schizophrenia in OCD- Open Label Study

NCT00456937 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2009-01-27

No results posted yet for this study

Summary

SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology

Conditions

Interventions

DRUG

Escitalopram

Sponsors & Collaborators

  • Lundbeck Israel

    collaborator INDUSTRY

  • BeerYaakov Mental Health Center

    lead OTHER_GOV

Principal Investigators

  • Rafael Octavio Stryjer, M.D. · Beer Yaakov Mental Health Center

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Israel

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00456937 on ClinicalTrials.gov